Article

Metabolic Profiling, Chemical Composition, Antioxidant Capacity, and In Vivo Hepato- and Nephroprotective Effects of Sonchus cornutus in Mice Exposed to Cisplatin

Sameh S. Elhady 1,*,†, Reda F. A. Abdelhameed 2,3,*,†, Eman T. Mehanna 4, Alaa Samir Wahba 4, Mahmoud A. Elfaky 1,5, Abdulrahman E. Koshak 1, Ahmad O. Noor 6, Hanin A. Bogari 6, Rania T. Malatani 6 and Marwa S. Goda 3

1 Department of Natural Products, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; melfaky@kau.edu.sa (M.A.E.); aekoshak@kau.edu.sa (A.E.K.)
2 Department of Pharmacognosy, Faculty of Pharmacy, Galala University, New Galala 43713, Egypt
3 Department of Pharmacognosy, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt; marwa_saeed@pharm.suez.edu.eg
4 Department of Biochemistry, Faculty of Pharmacy, Suez Canal University, Ismailia 41522, Egypt; eman.taha@pharm.suez.edu.eg (E.T.M.); alaa.samir@pharm.suez.edu.eg (A.S.W.)
5 Centre for Artificial Intelligence in Precision Medicines, King Abdulaziz University, Jeddah 21589, Saudi Arabia
6 Department of Pharmacy Practice, Faculty of Pharmacy, King Abdulaziz University, Jeddah 21589, Saudi Arabia; aonoor@kau.edu.sa (A.O.N.); hbogari@kau.edu.sa (H.A.B.); rmalatani@kau.edu.sa (R.T.M.)
* Correspondence: ssahmed@kau.edu.sa (S.S.E.); reda.fouad@gu.edu.eg (R.F.A.A.); Tel.: +966-544512552 (S.S.E.)
† These authors contributed equally to this work.

Abstract: Sonchus cornutus (Asteraceae) is a wild, edible plant that represents a plentiful source of polyphenolic compounds. For the first time, the metabolic analysis profiling demonstrated the presence of anthocyanidin glycosides, coumarins, flavonoids and their corresponding glycosides, and phenolic acids. The total phenolic compounds were determined to be 206.28 ± 1.46 mg gallic acid equivalent/gm, while flavonoids were determined to be 45.56 ± 1.78 mg quercetin equivalent/gm. The crude extract of S. cornutus exhibited a significant 1,1-diphenyl-2-picrylhydrazyl free radical scavenging effect with half-maximal inhibitory concentration (IC50) of 16.10 ± 2.14 µg/mL compared to ascorbic acid as a standard (10.64 ± 0.82 µg/mL). In vitro total antioxidant capacity and ferric reducing power assays revealed a promising reducing potential of S. cornutus extract. Therefore, the possible protective effects of S. cornutus against hepatic and renal toxicity induced by cisplatin in experimental mice were investigated. S. cornutus significantly ameliorated the cisplatin-induced disturbances in liver and kidney functions and oxidative stress, decreased MDA, ROS, and NO levels, and restored CAT and SOD activities. Besides, it reversed cisplatin-driven upregulation in inflammatory markers, including iNOS, IL-6, and IL-1β levels and NF-κB and TNF-α expression, and elevated anti-inflammatory IL-10 levels and Nrf2 expression. Additionally, the extract mitigated cisplatin alteration in apoptotic (Bax and caspase-3) and anti-apoptotic (Bcl-2) proteins. Interestingly, hepatic, and renal histopathology revealed the protective impacts of S. cornutus against cisplatin-induced pathological changes. Our findings guarantee a protective effect of S. cornutus against cisplatin-induced hepatic and renal damage via modulating oxidative stress, inflammation, and apoptotic pathways.

Keywords: Sonchus cornutus; polyphenolic compounds; hepatotoxicity; nephrotoxicity; oxidative stress; inflammation; apoptosis; drug discovery; industries development

1. Introduction

Cisplatin, a platinum-containing drug, is one of the most widely used chemotherapy-agents in the management of various types of cancer. The anticancer effect of
cisplatin is thought to be attributable to DNA adducts formation and G2 cell cycle arrest, eventually leading to apoptosis. However, its application and effectiveness are limited due to drug resistance as a result of reduced drug accumulation in cancer cells, glutathione, and metallothioneins-induced drug inactivation and accelerated repair of DNA lesions [1]. Another inherent challenge of cisplatin is that the dose scale required to overwhelm even a minor increase in cellular resistance can adversely affect normal cells and cause severe cytotoxicity, with nephrotoxicity being considered the principal dose-limiting side effect. More to the point, massive hepatic toxicity can occur with repeated higher doses of cisplatin [2].

Cisplatin-induced cytotoxicity has been attributed to enhanced oxidative stress and increased production of reactive oxygen species (ROS) which deplete glutathione levels and reduce activity of the antioxidant enzymes superoxide dismutase (SOD) and catalase. Moreover, ROS can impair cell integrity via lipid peroxidation, protein denaturation, and DNA damage [3]. In addition, involvement of proinflammatory genes such as tumor necrosis factor-α (TNF-α), inducible nitric oxide synthase (iNOS), mitochondrial dysfunction, disturbed Ca^{2+} homeostasis, and apoptosis have been demonstrated to exert crucial role in the mechanisms associated with cisplatin-induced cytotoxicity [4,5]. Considering that oxidative stress is a key insult associated with cisplatin-induced hepatic and renal toxicity, co-administering antioxidant agents is urgently needed to minimize potential side effects through inhibition of cisplatin-induced free radical generation [6].

Plant-based antioxidants with diverse pharmacological actions have come under extensive study. Asteraceae is one of the largest plant families, with above 1620 genera and 23,600 species around the world. Family Asteraceae demonstrated remarkable antioxidant, anti-inflammatory, antimicrobial, wound healing, and cytotoxic activities. Those beneficial pharmacological effects may be attributed to the chemical diversity of different metabolites such as polyphenols, phenolic acids, flavonoids, polysaccharides, and terpenes [7]. Genus Sonchus (Family: Asteraceae) is a class of edible wild plants that are widely spread in Europe, Asia, and Africa. The Sonchus species possess hepatoprotective, cardioprotective, anticancer, antioxidant, anti-inflammatory, and antimicrobial effects. Numerous bioactive metabolites (e.g., fatty acids, tocopherols, flavonoids, triterpenes, coumarins, steroids, and saccharides) were detected in Sonchus species [8]. *Sonchus cornutus* is an annual herb with hollow stem, sessile leaves, and large inflorescence. *S. cornutus* is commonly known as *Molieta* in Sudan and traditionally used for treatment of diabetes, hypertension, and malaria. The parasitic activity of *S. cornutus* against *Theileria lestoquardi* was previously observed. Previous studies have reported that the therapeutic dose (50–500 mg/Kg) of *S. cornutus* was safe and caused no hematological, biochemical, or histopathological harmful effects [9]. Despite the biological value and safety of edible *S. cornutus*, few chemical studies were performed.

Therefore, the present study was directed to detect the secondary metabolites in *S. cornutus* extract using liquid chromatography-tandem mass spectrometry (LC-MS/MS), analyze major chemical composition, and evaluate its in vitro antioxidant activity. The current study also evaluated the protective effect of *S. cornutus* crude extract against cisplatin-induced hepato- and nephro-toxicities in experimental mice.

2. Materials and Methods

2.1. Collection of Plant Material and Extraction Process

The whole plant was collected in November from Khartoum, Sudan. *S. cornutus* was air dried, finely ground, and then was subjected to cold maceration with methyl alcohol (70%; 3 × 1000 mL) at room temperature. The combined hydroalcoholic solutions were concentrated under vacuum to give a crude extract of 75 gm weight.
2.2. Metabolic Profiling and Chemical Analysis of *S. cornutus*

2.2.1. LC-MS/MS Metabolic Profiling

The metabolic profiling and composition were established using (HPLC/Triple-TOF-MS/MS) as mentioned before [10–14]. Detailed methodology is provided in Supplementary Materials.

2.2.2. Total Phenolics Content Assay

Folin–Ciocalteu (Folin-C) spectrophotometric method was applied for determination of total polyphenolics content. Briefly, an amount of 500 µL of crude extract of *S. cornutus* was mixed with 2.5 mL of Folin-C reagent (10%) and then 2 mL of sodium carbonate (7.5%) was added after 5 min. The reaction was allowed to complete for 2 h in darkness at 25 °C [15]. The intensity of the resulting blue color was measured spectrophotometrically at 760 nm using distilled water as a blank. The experiment was replicated three times. The total phenolic content of *S. cornutus* was calculated in comparison with a calibration curve using gallic acid as a standard; therefore, the values are expressed as gallic acid equivalent per gram extract (mg GAE/gm).

2.2.3. Total Flavonoids Content Assay

Aluminum complexation reaction was applied for determination of total flavonoids content. A volume of 1 mL of *S. cornutus* sample was mixed with 4 mL of distilled water and 0.3 mL of sodium nitrite solution (5%). After 5 min, 0.3 mL of AlCl₃·6H₂O solution (10%) was added and the mixture was incubated for 5 min at 25 °C. Finally, 2 mL of 1 M NaOH solution was added, and the total volume was completed to 10 mL with distilled water. The intensity of yellowish orange color was recorded spectrophotometrically at 510 nm using distilled water as a blank [16]. Additionally, the experiment was repeated three times. The total flavonoids content of *S. cornutus* was calculated in comparison with a calibration curve using quercetin as a standard; therefore, the values are expressed as quercetin equivalent per gram extract (mg QE/gm).

2.3. In Vitro Antioxidant Assays

2.3.1. Determination of Total Antioxidant Capacity

Phosphomolybdenum assay was conducted for evaluation of total antioxidant capacity of *S. cornutus*. This method was carried out as follows: A volume of 0.3 mL of methanolic crude extract of *S. cornutus* was mixed with 2.7 mL of phosphomolybdenum reagent solution. The reagent solution was prepared by mixing 28 mM sodium phosphate and 4 mM ammonium molybdate in 0.6 M sulfuric acid. Then, the sample–reagent mixture was capped and incubated for 90 min at 95 °C. After the reaction time, the mixture was cooled for 20 min at ambient temperature and then the intensity of green color was recorded spectrophotometrically at 695 nm using methanol as a blank [17]. The experiment was done in triplicate and a calibration curve using gallic acid was produced; the values were expressed as gallic acid equivalent per gram extract (mg GAE/gm). Ascorbic acid was used as a reference control.

2.3.2. Ferric Reducing Antioxidant Power Assay

The reducing potential of *S. cornutus* was performed through mixing 2 mL of crude extract, 2 mL of sodium phosphate buffer solution (0.2 M; pH = 6.6), and 2 mL of potassium ferricyanide (10 mg/L). The reaction mixture was incubated for 20 min at 50 °C. Then, the mixture was acidified using 2 mL of trichloroacetic acid (100 mg/L) and centrifuged. A volume of 2 mL of the supernatant was collected, diluted with 2 mL of distilled water and 0.4 mL of ferric chloride (0.1%), and then incubated for 10 min. The intensity of the color was measured spectrophotometrically at 700 nm using methanol as a blank [18]. The experiment was also done in triplicate. The reducing potential of *S. cornutus* was calculated in comparison with a calibration curve using 1 mM ferrous sulphate; therefore, the values
are expressed as mM ferrous equivalent per gram extract (mmol Fe\(^{2+}\)/gm) \[19\]. Ascorbic acid was applied as a reference standard.

2.3.3. DPPH Radical Scavenging Assay
The free radical scavenging activity of *S. cornutus* was evaluated via mixing equal volumes of the crude extract with 1,1-diphenyl-2-picrylhydrazyl (DPPH) free radical (200 µM). The reaction mixture was incubated for 30 min in darkness at 30 °C. The intensity of yellow color was measured spectrophotometrically at 516 nm using methanol as a blank. The experiment was also done in triplicate. The scavenging percentage was calculated based on the following equation: \[(A_{\text{control}} - A_{\text{sample}})/A_{\text{control}} \times 100\], where \(A_{\text{control}}\) is the absorbance of the DPPH solution only, and \(A_{\text{sample}}\) is the absorbance of both DPPH solution and the sample at different concentrations (5–1000 µg/mL) \[17\]. The value of IC\(_{50}\) (the concentration that is required to inhibit initial concentration of DPPH by 50%) was determined by a linear concentration/percentage inhibition curve. Ascorbic acid was also applied as a reference standard.

2.4. In Vivo Study of *S. cornutus*

2.4.1. Drugs and Chemicals
Cisplatin (50 mg/50 mL) vial was purchased from Mylan Company (Saint Priest, France). Phosphate buffered saline solution (PBS) was obtained from Lonza Bio-products (Verviers, Belgium).

2.4.2. Experimental Animals and Study Protocol
Experimental design and animal handling were carried out in accordance with Guide for the Care and Use of Laboratory Animals (8th edition, National Academies Press) and were approved by the Ethics Committee of Faculty of Pharmacy, Suez Canal University (Ethics code: 202103RA2).

Thirty-two male Swiss albino mice with an average weight of 25 ± 5 g, obtained from the Faculty of Veterinary Medicine, Suez Canal University, Ismailia, Egypt, were utilized in this study. Mice were accommodated in stainless steel rodent cages under controlled room temperature (25 ± 2 °C) with a 12 h light–dark cycle. Mice were kept on standard rat chow and tap water. They were kept for a one-week adaptation period. After the acclimatization period, mice were randomly divided into four groups (eight animals each). The first and second groups received saline orally once daily for 3 weeks, and on the 15th day of the experiment, received a single intraperitoneal (i.p.) injection of isotonic saline or cisplatin (7.5 mg/kg) \[20\], serving as the normal control and cisplatin groups, respectively. The third and fourth groups received *S. cornutus* extract (250 mg/kg/day; orally) and (500 mg/kg/day; orally), respectively, for 3 weeks, starting 14 days before giving a single i.p. injection of cisplatin (7.5 mg/kg).

At the end of the experiment, the animals were overnight-fasted, and blood samples were collected from the retro-orbital plexus under mild ketamine anesthesia. Samples were left to clot and then centrifuged for 20 min at (2000 \( \times \) g/4 °C) for serum separation. The obtained sera were kept at −80 °C until used to assess alanine aminotransferase (ALT), aspartate aminotransferase (AST), and alkaline phosphatase (ALP) activities, total protein, albumin, blood urea nitrogen (BUN), and serum creatinine. Later, mice were sacrificed by decapitation and their mice liver and kidneys were dissected out, weighed, and washed with saline, then divided into three portions: one portion was fixed in 10% buffered formalin. After that, the formalin-fixed samples were washed with tap water, immersed in ethyl alcohol serial dilutions, embedded in paraffin, and cut into sections (4–5 µm thickness) using a rotatory microtome for histopathological and immunohistochemical analysis. The second portion was homogenized in phosphate buffer (pH 7.4), then centrifuged at (2000 \( \times \) g/4 °C) for 15 min. The resulting supernatant was stored at −80 °C for further biochemical analysis. The third portion was homogenized in Qiazol reagent and used for quantitative PCR analysis.
2.5. Biochemical Estimations and Histopathological Examination

2.5.1. Assessment of Liver and Kidney Functions

Serum levels of ALT, AST, ALP, creatinine, and BUN were measured by routine colorimetric methods using commercial diagnostic kits (Diamond Diagnostics, Cairo, Egypt) according to the manufacturer’s data protocols.

2.5.2. Assessment of Hepatic and Renal Oxidative Stress and Inflammatory Markers

In the liver and kidney homogenates of all groups, malondialdehyde (MDA) levels and catalase and SOD activities were measured using colorimetric assay kits obtained from Biodiagnostic Co. (Dokki, Giza, Egypt; Cat. No. MD 2529 for MDA, CA 2517 for catalase and SD 2521 for SOD) in accordance with manufacturer’s instructions.

Levels of ROS, reduced glutathione (GSH), and oxidized glutathione (GSSG) were determined in the tissue homogenates of both liver and kidney by mouse-specific enzyme-linked immunosorbent assay (ELISA) kits (MyBioSource, San Diego, CA, USA; Cat. No. MBS2601061, MBS724815, and MBS749109, respectively). Levels of GSH and GSSG were used to calculate the GSH/GSSG ratio in the liver and the kidney of the experimental mice.

Nitric oxide (NO) levels were determined in tissue homogenate spectrophotometrically (Biodiagnostic, Egypt; Cat. No. NO 2533). Hepatic and renal iNOS was determined using mouse-specific ELISA kits (MyBioSource, San Diego, CA, USA; Cat. No. MBS263618).

Interleukin (IL)-6, IL-1β, and IL-10 were measured using mouse-specific ELISA kits purchased from MyBioSource (San Diego, CA, USA; Cat. No. MBS730957, MBS701092, and MBS018124, respectively), following manufacturer’s instructions.

2.5.3. Quantitative Real-Time—PCR Analysis of Nuclear Factor kappa B (NF-κB), Tumor Necrosis Factor-α (TNF-α), and Nuclear Factor Erythroid 2-related Factor 2 (Nrf2) Expression

Total RNA was extracted from hepatic and renal tissues using miRNeasy Mini Isolation kit (Qiagen, Hilden, Germany) according to the manufacturer’s protocol and quantified spectrophotometrically using the NanoDrop ND-1000 (NanoDrop Tech., Wilmington, DE, USA) at 260/280 nm. NF-κB, TNF-α, and Nrf2 expressions were assayed using GoTaq® 1-Step RT-qPCR System (Promega, Madison, USA) with the target genes’ expression compared to β-actin mRNA gene expression as a reference control. According to the manufacturer’s instructions, the total volume of the reaction was 20 µL containing 10 µL of GoTaq® qPCR master mix, 0.4 µL of GoScript™ RT mix for 1-step RT-qPCR, 2 µL of forward and reverse primers, 0.31 µL of CXR reference dye, 4 µL of RNA template and 3.29 µL of nuclease-free water. The GenBank accession No., primers, and annealing temperatures are listed in Table S1.

The thermal cycler conditions were 15 min at 37 °C (reverse transcription), 10 min at 95 °C (reverse transcriptase inactivation), 40 cycles of 10 s at 95 °C (denaturation), 30 s at the specified annealing temperature (annealing), 30 s at 72 °C (extension), and one cycle for 10 min at 72 °C (final extension). The reaction for each sample was run in duplicate, and a no-template control was run for all samples. The fold change was determined according to the comparative cycle threshold method (ΔΔCT method) [21].

2.5.4. Immunohistochemistry for Detection of Bax, Bcl-2, and Caspase-3

Sections of the liver and kidney tissues were deparaffinized and dehydrated sequentially in graded ethyl alcohol. After that, sections were autoclaved at 121 °C in distilled water for 5 min to unmask antigen sites. Then, the slides were immersed in 3% H2O2 for quenching the endogenous peroxidase activity and blocked in 5% bovine serum albumin blocking reagent for 20 min after rinsing 3 times in PBS to stop non-specific reactions. The blocking slides were incubated overnight at 4 °C with anti-Bax, anti-Bcl-2, and anti-caspase 3 antibodies (Invitrogen Life technologies, Carlsbad, CA, USA, Cat. No. 33-6400, MA5-15668, and 43-7800, respectively) diluted in PBS, followed by secondary antibody incubation for 30 min. Bound antibodies were detected by incubation for 45 min with avidin–biotin
complex (ABC kit, Vector Laboratories, Burlingame, CA, USA) at 37 °C. Visualization of the reaction product was achieved by treatment with diaminobenzidine substrate (Sigma Chemical Company, St. Louis, MO, USA) and counterstaining with Mayer’s hematoxylin. Proteins’ expression was observed under light microscopy (Olympus BX-60, Tokyo, Japan). Quantification of positive areas was carried out using image analysis system Leica Qwin DW3000 (LEICA Imaging Systems Ltd., Cambridge, UK). Five fields/each slide were measured in all groups. The positive staining intensity was measured as the ratio of the stained area to the entire field.

2.5.5. Histopathological Examination

The cut sections obtained from the prepared blocks were stained with hematoxylin and eosin (H&E) and visualized under a light microscope for examination of hepatic and renal histological structure.

2.5.6. Statistical Analysis

Statistical analysis was performed using the Statistical Package for Social Sciences, SPSS (IBM, Armonk, NY, USA), v. 21.0 software. Values were expressed as the mean ± standard deviation (SD). One-way analysis of variance (ANOVA) followed by Bonferroni’s post hoc test was used for statistical comparisons. A statistically significant difference was indicated by a p value less than 0.05.

3. Results and Discussion

3.1. LC-MS/MS Metabolic Profiling of Crude Extract of S. cornutus

Liquid chromatography-tandem mass spectrometry (LC-MS/MS) is an informative bioanalytical chromatographic tool based on physical separation of metabolites of different classes followed by mass fragmentation-based identification. The tandem mass spectrometry and mass error accuracy are sufficient interpretative parameters for identification of deduced compounds [10,11]. The current LC-MS/MS study of the crude extract of S. cornutus was developed for the first time. The metabolomic analysis (Figures S1 and S2) revealed the prevalence of polyhydroxylated phenolic compounds such as anthocyanidin glycosides, coumarins and their glycosides, flavonoids and their glycosides, and phenolic acids (Table 1, Figure 1).

Table 1. Metabolic profiling of the crude extract of S. cornutus using LC-MS/MS analysis.

| No | Polarity Mode | MZmine ID | Ret. Time (min) | Measured m/z | Calculated m/z | Mass Error (ppm) | Adduct | Molecular Formula | MS/MS Spectrum | Deduced Compound | Ref. |
|----|---------------|-----------|----------------|--------------|---------------|-----------------|--------|------------------|----------------|----------------|------|
| 1. | Positive      | 2385      | 5.43           | 611.1656     | 611.1607      | 8.02            | M *    | C_{27}H_{31}O_{16} * | 611, 449, 287 | Cyanidin-3, 5-di-O-glucopyranoside | [22] |
| 2. | Positive      | 2563      | 6.33           | 595.1599     | 595.1657      | −9.75           | M *    | C_{27}H_{31}O_{15} * | 595, 433, 287 | Cyanidin-3-O-rutinoside | [22] |
| 3. | Positive      | 2660      | 6.49           | 581.1516     | 581.1501      | 2.58            | M *    | C_{26}H_{29}O_{14} * | 581, 449, 287 | Cyanidin-3-O-(2”-O-furfurylpyranosyl-β-glucopyranoside) | [22] |
| 4. | Positive      | 2672      | 6.51           | 465.1022     | 465.1028      | −1.29           | M *    | C_{21}H_{21}O_{13} * | 465, 303 | Delphinidin-3-glucoside | [23] |
| 5. | Positive      | 3059      | 7.81           | 463.1282     | 463.1235      | 10.15           | M *    | C_{22}H_{22}O_{13} * | 463, 301 | Peonidin-3-O-glucoside | [24] |
| 6. | Positive      | 3103      | 7.99           | 449.1082     | 449.1078      | 0.89            | M *    | C_{21}H_{21}O_{12} * | 449, 287 | Cyanidin-3-O-glucoside | [22] |
Table 1. Cont.

| No | Polarity Mode | MZmine ID | Ret. Time (min) | Measured m/z | Calculated m/z | Mass Error (ppm) Adduct | Molecular Formula | MS/MS Spectrum | Deduced Compound | Ref. |
|----|---------------|-----------|----------------|--------------|---------------|-------------------------|------------------|----------------|----------------|------|
| II. Coumarins and their glycosides |
| 7. Positive | 2122 | 3.73 | 341.0866 | 341.0873 | −2.05 | [M + H]⁺ | C₁₅H₂₀O₁₀ | 341, 179, 133 | Daphnetin-8-glucopyranoside | [25] |
| 8. Negative | 2357 | 3.79 | 339.0732 | 339.0716 | 4.72 | [M − H]⁻ | C₁₅H₁₉O₄ | 339, 177 | Aesculin | [11] |
| 9. Negative | 2547 | 5.07 | 177.0192 | 177.0188 | 2.26 | [M − H]⁻ | C₉H₆O₄ | 177, 89 | Aesculetin | [26] |
| 10. Positive | 3035 | 5.75 | 179.0356 | 179.0344 | 6.70 | [M + H]⁺ | C₉H₆O₄ | 179, 133, 77 | Daphnetin | [25] |
| 11. Negative | 2757 | 6.01 | 207.0293 | 207.0293 | 0.0 | [M − H]⁻ | C₁₀H₈O₅ | 207, 192 | Fraxetin | [26] |
| III. Flavonoids and their glycosides |
| 12. Negative | 2910 | 6.52 | 593.1481 | 593.1506 | −4.21 | [M − H]⁻ | C₂₇H₂₉O₁₅ | 593, 285 | Datiscin | [10] |
| 13. Negative | 3045 | 6.85 | 447.0922 | 447.0927 | −1.12 | [M − H]⁻ | C₂₁H₂₀O₁₁ | 447, 327 | Orientin | [11] |
| 14. Negative | 3564 | 9.43 | 285.0404 | 285.0399 | 1.75 | [M − H]⁻ | C₁₅H₁₀O₆ | 285, 133 | Luteolin | [11] |
| 15. Positive | 3505 | 9.72 | 287.0574 | 287.0556 | 6.27 | [M + H]⁺ | C₁₅H₁₀O₆ | 287, 269, 241, 213, 145, 137 | Fisetin | [11] |
| IV. Phenolic derivatives |
| 16. Negative | 383 | 1.14 | 311.0427 | 311.0403 | 7.72 | [M − H]⁻ | C₁₃H₁₂O₅ | 311, 133 | Caftaric acid | [27] |
| 17. Negative | 973 | 1.24 | 179.0355 | 179.0344 | 6.14 | [M − H]⁻ | C₉H₆O₄ | 179, 135, 134 | Caffeic acid | [11] |
| 18. Negative | 2496 | 4.62 | 359.0758 | 359.0767 | −2.51 | [M − H]⁻ | C₁₅H₁₀O₆ | 359, 161 | Rosmarinic acid | [28] |
| 19. Negative | 2536 | 4.88 | 353.0860 | 353.0873 | −3.68 | [M − H]⁻ | C₁₄H₁₄O₇ | 353, 191 | Chlorogenic acid | [29] |
| V. Other chemical classes |
| 20. Positive | 1680 | 1.39 | 138.0546 | 138.0555 | −6.52 | [M + H]⁺ | C₇H₇NO₂ | 138, 94 | Trigonelline | [10] |
| 21. Negative | 4434 | 22.81 | 455.3539 | 455.3525 | 3.07 | [M − H]⁻ | C₂₉H₄₀O₉ | 455 | Ursolic acid | [11] |

Polyphenols are well-known for their antioxidant and anti-carcinogenic activities, so they draw great attention of scientific research for health care. The detected metabolites were previously reported to play a crucial role in prevention and treatment of several diseases. Briefly, cyanidin-3-O-rutinoside inhibited α-glucosidase enzyme, resulting in lowering postprandial hyperglycemia in diabetic rats [30]. Delphindin-3-glucoside suppressed the expression of HOTAIR, a diagnostic biomarker for several cancer types [31]. Furthermore, the in silico study of peonidin-3-O-glucoside demonstrated anti-inflammatory activity through binding to TNF-α receptor and subsequently inhibiting TNF-α signaling [32]. Additionally, cyanidin-3-O-glucoside exhibited a protective mechanism against intestinal injury through its antioxidant and anti-inflammatory properties. These biological activities were declared through upregulation of glutathione and downregulation of both cyclooxygenase-2 and iNOS. Additionally, the cytotoxic potential of cyanidin-3-O-glucoside referred to angiogenesis suppression, apoptosis induction, and downregulation of proapoptotic factors as Bax and caspases [33]. Concerning the detected coumarins and their glycosides, esculetin showed antiviral activity against human immunodeficiency (HIV) virus [34], while esculin showed significant antimicrobial activity against Gram-positive bacteria [35]. Daphnetins hold anti-inflammatory, antithrombotic, immunosuppressive, and anti-Helicobacter pylori activities [36–38]. Additionally, fraxetin exhibited antibacterial activity against Staphylococcus aureus [39] and induced apoptosis in colon cancer cells [40]. Regarding the detected flavonoids and their glycosides, orientin was found to be a promising antimicrobial, anti-inflammatory, cardioprotective, and anti-obesity...
The anti-inflammatory effect of luteolin was discussed through suppression of cyclooxygenase-2 [42] while fisetin suppressed mast cells activation which are involved in inflammatory response [43]. Referring to phenolic acids, caffeic acid exhibited innumerable physiological activities such as antioxidant, anti-inflammatory, antibacterial, immunomodulatory, hepatoprotective, anticancer, and anti-atherosclerotic activities [44]. Rosmarinic acid is a promising candidate for treatment of liver fibrosis through suppression of pro-inflammatory and fibrotic markers [45]. Chlorogenic acid is a potent antimicrobial, anti-obesity, anti-inflammatory, hepatoprotective, neuroprotective, and cardioprotective medicinal agent [46]. Ursolic acid was also shown to be an anti-inflammatory, antitumor, and antimicrobial agent [47]. The previously reported antioxidant properties of different species of genus *Sonchus* were correlated to the polyphenolic active metabolites [48–50]. Therefore, quantitative analysis of polyphenols in *S. cornutus* was a must for our study.

Figure 1. Structures of the detected metabolites as listed in Table 1.
3.2. Quantification of Total Phenolics and Total Flavonoids in *S. cornutus*

Phenolic compounds are widely spread secondary metabolites in plants. Polyphenols exhibit numerous pharmacological health benefits as they act as antioxidants through scavenging free radicals [51]. Their antioxidant effect defends against inflammation and oxidative stress-induced diseases, cancer, diabetes, aging, pulmonary, cardiovascular, and neurological disorders [52]. Based on the predominance of polyphenolic compounds in the above-mentioned LC-MS/MS analysis, there was a deep need to quantify both total phenolics and total flavonoids in *S. cornutus*. From data shown in Table 2, it was found that the crude extract of *S. cornutus* is an enriched source of polyphenols which were determined to be 206.28 ± 14.64 mg gallic acid equivalent/gm extract for total phenolics and 45.56 ± 1.78 mg quercetin equivalent/gm extract for total flavonoids.

| Crude Extract          | Total Phenolics (mg GAE/gm) | Total Flavonoids (mg QE/gm) |
|------------------------|-----------------------------|-----------------------------|
| *S. cornutus* crude extract | 206.28 ± 14.64              | 45.56 ± 1.78                |

GAE: gallic acid equivalent; QE: quercetin equivalent.

These findings are in accordance with those found in *Sonchus asper*, in which total phenolics and total flavonoids were found at concentrations of 332 ± 1.53 mg gallic acid equivalent/gm dry extract and 11.4 ± 0.45 mg rutin equivalent/gm dry extract, respectively [53]. It can be declared that *Sonchus* species are rich in flavonoids and other polyphenolic compounds such as tannins [54], coumarins, and phenolic acids [55].

3.3. In Vitro Antioxidant Activity of *S. cornutus*

The polyphenolic compounds are renowned for their antioxidant activity. Therefore, the in vitro antioxidant activity of *S. cornutus* was determined for the first time by using three different methods: total antioxidant capacity, ferric reducing power capacity, and DPPH free radical scavenging activity assays. Among them, the DPPH scavenging activity test illustrates the ability of *S. cornutus* to donate proton to the violet solution of DPPH forming stable yellow solution of 1,1-diphenyl-2-picrylhydrazine [56]. Unlike DPPH assay, total antioxidant capacity and reducing power activity are based on the ability of *S. cornutus* to reduce molybdenum VI to molybdenum V or ferric to ferrous, respectively [56]. From data shown in Table 3, the crude extract of *S. cornutus* showed a significant DPPH free radical scavenging activity with IC$_{50}$ of 16.10 ± 2.14 µg/mL when compared to ascorbic acid (10.64 ± 0.82 µg/mL) as a reference standard. This can be explained by *Sonchus* species’ richness of polyphenolic compounds [54] that can easily donate proton to stabilize DPPH free radical.

Table 3. Total antioxidant capacity, ferric reducing power activity, and DPPH free radical scavenging activity of *S. cornutus*.

| Samples                  | Total Antioxidant Capacity (mg GAE/gm) | Ferric Reducing Power (mM Fe$^{3+}$/gm) | IC$_{50}$ of DPPH Scavenging Activity (µg/mL) |
|--------------------------|---------------------------------------|----------------------------------------|-----------------------------------------------|
| *S. cornutus* crude extract | 49.06 ± 3.62                         | 1.92 ± 0.71                            | 16.10 ± 2.14                                  |
| Ascorbic acid            | 69.32 ± 4.51                          | 3.14 ± 0.82                            | 10.64 ± 0.82                                  |

GAE: gallic acid equivalent; DPPH: 1,1-diphenyl-2-picrylhydrazyl.

Moreover, the crude extract of *S. cornutus* exhibited moderate reducing potential that was evaluated via total antioxidant capacity and ferric reducing power assays. The ferric reducing power activity of *S. cornutus* was 1.92 ± 0.71 mM Fe$^{3+}$/gm while the total antioxidant capacity was 49.06 ± 3.62 mg GAE/gm (Table 3). Based on the hopeful in vitro antioxidant effect of the crude extract of *S. cornutus*, further in vivo assessment
of hepatoprotective and nephroprotective effects of S. cornutus against cisplatin-induced toxicity was held.

3.4. The Effects of the Crude Extract of S. cornutus against Cisplatin-Induced Hepatic and Renal Toxicity in Experimental Mice

Investigation of the liver and kidney functions in the sera of the experimental mice revealed that administration of cisplatin (7.5 mg/kg) alone caused a significant increase in the serum levels of ALT, AST, ALP, creatinine, and BUN relative to the normal control group (p < 0.05). Mice that received both doses of the crude extract of S. cornutus (250 and 500 mg/kg) before a single dose (7.5 mg/kg) of cisplatin had significantly lower levels of all those markers compared to the cisplatin control group. The levels of all the detected liver and kidney markers were significantly lower in the group that received higher dose (500 mg/kg) of S. cornutus extract compared to the group that received the lower dose (250 mg/kg) (Table 4).

Table 4. The effect of S. cornutus crude extract on the liver and kidney functions in the experimental mice.

| Parameter          | Normal Control | Cisplatin (7.5 mg/kg) | S. cornutus (250 mg/kg) | S. cornutus (500 mg/kg) |
|--------------------|----------------|-----------------------|------------------------|------------------------|
| ALT (U/L)          | 51.55 ± 5.60   | 98.11 ± 10.10 *       | 76.13 ± 8.20 *#        | 63.12 ± 6.22 *#        |
| AST (U/L)          | 45.93 ± 5.50   | 92.77 ± 9.98 *        | 77.37 ± 8.23 *#        | 60.21 ± 7.05 *#        |
| ALP (U/L)          | 91.54 ± 8.73   | 280.38 ± 21.39 *      | 210.20 ± 18.28 *#      | 140.28 ± 15.30 *#      |
| Creatinine (mg/dL) | 0.16 ± 0.03    | 0.44 ± 0.09 *         | 0.35 ± 0.07 *#         | 0.22 ± 0.05 *#         |
| BUN (mg/dL)        | 45.34 ± 3.18   | 79.90 ± 9.23 *        | 63.36 ± 7.22 *#        | 51.29 ± 5.82 *#        |

Data are expressed as mean ± SD and analyzed using one-way ANOVA followed by Bonferroni’s post hoc test (n = 8). ALT = alanine aminotransferase; AST = aspartate aminotransferase; ALP = alkaline phosphatase; BUN = blood urea nitrogen; * significantly different vs. the normal control group; # significantly different vs. the cisplatin group; ^ significantly different vs. the S. cornutus (250 mg/kg) group. Differences were considered significant at p < 0.05.

The antioxidant and anti-inflammatory properties of the crude extract of S. cornutus in the cisplatin receiving mice were assessed. As expected, cisplatin caused a significant increase of the levels of MDA, ROS, NO, and iNOS, and a significant decrease of GSH/GSSG ratio, SOD, and catalase in both the liver and kidney tissues compared to the normal control group (p < 0.05) (Table 5).
Table 5. The effect of *S. cornutus* crude extract on the levels of oxidative stress markers in the liver and kidney tissues of the experimental mice.

| Parameter          | Organ   | Normal Control | Cisplatin (7.5 mg/kg) | *S. cornutus* (250 mg/kg) | *S. cornutus* (500 mg/kg) |
|--------------------|---------|----------------|-----------------------|---------------------------|---------------------------|
| MDA (nmol/g tissue) | Liver   | 40.4 ± 5.1     | 327.7 ± 32.5 *        | 18.2 ± 21.3 * f           | 136.3 ± 15.4 * f          |
|                    | Kidney  | 122.4 ± 12.3   | 558.3 ± 63.3 *        | 30.2 ± 32.3 * f           | 162.4 ± 18.3 * f          |
| ROS (U/g tissue)   | Liver   | 17.2 ± 2.0     | 56.1 ± 5.9 *          | 29.8 ± 3.0 * f            | 23.4 ± 2.5 * f            |
|                    | Kidney  | 15.9 ± 1.8     | 55.3 ± 5.8 *          | 33.1 ± 3.4 * f            | 25.8 ± 2.8 * f            |
| GSH (ng/mg tissue) | Liver   | 70.2 ± 8.1     | 21.3 ± 2.1 *          | 38.9 ± 4.2 * f            | 54.6 ± 6.3 * f            |
|                    | Kidney  | 59.2 ± 6.5     | 17.8 ± 1.9 *          | 28.7 ± 3.1 * f            | 41.2 ± 4.2 * f            |
| GSSG (ng/mg tissue)| Liver   | 19.7 ± 2.2     | 67.3 ± 7.5 *          | 36.5 ± 3.8 * f            | 28.7 ± 3.2 * f            |
|                    | Kidney  | 20.1 ± 2.2     | 63.2 ± 6.8 *          | 38.4 ± 4.0 * f            | 27.6 ± 2.8 * f            |
| GSH/GSSG ratio     | Liver   | 3.6 ± 0.5      | 0.3 ± 0.1 *           | 1.1 ± 0.1 * f             | 1.9 ± 0.2 * f             |
|                    | Kidney  | 2.9 ± 0.4      | 0.3 ± 0.1 *           | 0.7 ± 0.1 * f             | 1.5 ± 0.2 * f             |
| SOD (U/g tissue)   | Liver   | 698.9 ± 73.3   | 270.4 ± 30.2 *        | 398.2 ± 42.1 * f          | 470.7 ± 45.3 * f          |
|                    | Kidney  | 187.3 ± 2.2    | 117.2 ± 12.3 *        | 125.2 ± 14.2 *            | 150.3 ± 16.2 * f          |
| Catalase (U/g tissue) | Liver  | 16.8 ± 2.3    | 5.1 ± 0.7 *           | 9.2 ± 1.1 * f             | 13.2 ± 1.5 * f            |
|                    | Kidney  | 18.9 ± 2.5     | 8.1 ± 0.9 *           | 10.9 ± 1.2 * f            | 15.3 ± 1.7 * f            |
| NO (μmol/g tissue) | Liver   | 11.3 ± 1.6     | 44.5 ± 5.4 *          | 23.5 ± 2.8 * f            | 18.6 ± 2.0 * f            |
|                    | Kidney  | 8.6 ± 0.9      | 27.2 ± 3.2 *          | 21.3 ± 2.6 * f            | 14.6 ± 1.5 * f            |
| iNOS (ng/g tissue) | Liver   | 3.5 ± 0.4      | 16.5 ± 2.0 *          | 10.4 ± 1.4 * f            | 7.6 ± 0.9 * f             |
|                    | Kidney  | 3.4 ± 0.5      | 11.2 ± 1.3 *          | 7.7 ± 0.9 * f             | 5.9 ± 0.7 * f             |

Data are expressed as mean ± SD and analyzed using one-way ANOVA followed by Bonferroni’s post hoc test (n = 8). MDA = malondialdehyde; ROS = reactive oxygen species; GSH = reduced glutathione; GSSG = oxidized glutathione; SOD = superoxide dismutase; NO = nitric oxide; iNOS = inducible nitric oxide synthase; * significantly different vs. the normal control group; # significantly different vs. the cisplatin group; ¶ significantly different vs. the *S. cornutus* (250 mg/kg) group. Differences were considered significant at p < 0.05.

Both doses (250 and 500 mg/kg) of *S. cornutus* significantly decreased the levels of MDA, ROS, GSSG, NO, and iNOS, and increased concentrations of GSH, SOD, and catalase in the liver tissue in comparison with the cisplatin control group. The higher dose of *S. cornutus* (500 mg/kg) significantly decreased levels of MDA and iNOS and increased the ratio of GSH/GSSG and the activity of catalase in the liver tissue relative to the *S. cornutus* (250 mg/kg) group (Table 5).

In the renal tissue, both doses of *S. cornutus* crude extract lowered the GSH/GSSG ratio and decreased the levels of MDA, ROS, and iNOS compared to the cisplatin control group, however, only mice that received 500 mg/kg of *S. cornutus* extract had significantly higher SOD and catalase and lower NO in the kidney tissue relative to the cisplatin control group. The higher dose of *S. cornutus* (500 mg/kg) produced a more significant lowering of MDA, ROS, and the GSH/GSSG ratio compared to the 250 mg/kg *S. cornutus* dose (Table 5).

Interestingly, catalase levels in both the liver and renal tissues of the *S. cornutus* (500 mg/kg) group were not significantly different compared to the normal control group (Table 5).

Additionally, the expression of NF-κB and TNF-α and the protein levels of IL-1β and IL-6 were significantly higher in both the liver and kidney tissues of the mice that received cisplatin (7.5 mg/kg) only compared to the normal control group, whereas the expression of Nrf2 and the levels of IL-10 were significantly lower in both tissues of the cisplatin control group relative to the normal mice (p < 0.05). Administration of either doses (250 mg/kg and 500 mg/kg) of *S. cornutus* crude extract significantly decreased the
expression of NF-κβ and TNF-α, as well as the levels of IL-1β and IL-6, but significantly increased the expression of Nrf2 and the levels of IL-10 in both the liver and kidney tissues compared to the cisplatin control group (Figures 2 and 3).

**Figure 2.** The effect of S. cornutus crude extract on the expression and protein levels of inflammatory markers in the liver tissue of the experimental mice. (A) NF-κβ and TNF-α expression, (B) Nrf2 expression, (C) IL-1β, IL-6, and IL-10 levels. NF-κβ = nuclear factor kappa B; TNF-α = tumor necrosis factor-alpha; Nrf2 = nuclear factor-erythroid factor 2-related factor 2; IL = interleukin. Data are expressed as mean ± SD and analyzed using one-way ANOVA followed by Bonferroni’s post hoc test (n = 8). * significantly different vs. the normal control group; # significantly different vs. the cisplatin group; ^ significantly different vs. the S. cornutus (250 mg/kg) group. Differences were considered significant at p < 0.05.

In the liver tissue, the group that was given 500 mg/kg of *S. cornutus* had significantly lower NF-κβ expression and lower IL-1β and IL-6 levels, but significantly higher Nrf2 expression and IL-10 levels compared to the *S. cornutus* (250 mg/kg) group. Expression of TNF-α in the liver of *S. cornutus* (500 mg/kg) group showed no significant difference relative to the normal control group (Figure 2).
In the renal tissue, the *S. cornutus* (500 mg/kg) receiving mice had significantly lower IL-6 and significantly higher IL-10 levels compared to the *S. cornutus* (250 mg/kg) group. Interestingly, the expression of NF-κβ in the kidney tissue of the group that received 500 mg/kg of *S. cornutus* crude extract was not significantly different compared to the normal control group. Moreover, the expression levels of TNF-α and Nrf2 in both groups that received the lower and higher doses of *S. cornutus* were not significantly different relative to the normal control group (Figure 3).

The apoptotic effect of cisplatin was evidenced by the significantly increased expression of caspase-3 (Figure 4) and Bax (Figure 5), and decreased expression of Bcl-2 (Figure 6) in both the liver and kidney tissues of the cisplatin group in comparison to the normal control group. Immunohistochemical assessment showed that administration of 250 mg/kg of the crude extract of *S. cornutus* significantly downregulated caspase-3 (Figure 4) and

**Figure 3.** The effect of *S. cornutus* crude extract on the expression and protein levels of inflammatory markers in the kidney tissue of the experimental mice. (A) NF-κβ and TNF-α expression, (B) Nrf2 expression, (C) IL-1β, IL-6, and IL-10 levels. NF-κβ = nuclear factor kappa B; TNF-α = tumor necrosis factor-α; Nrf2 = nuclear factor-erythroid factor 2-related factor 2; IL = interleukin. Data are expressed as mean ± SD and analyzed using one-way ANOVA followed by Bonferroni’s post hoc test (n = 8). * significantly different vs. the normal control group; # significantly different vs. the cisplatin group; † significantly different vs. the *S. cornutus* (250 mg/kg) group. Differences were considered significant at p < 0.05.
upregulated Bcl-2 expression (Figure 6) in the liver tissue only relative to the cisplatin control group. The higher dose (500 mg/kg) of *S. cornutus* significantly downregulated caspase-3 (Figure 4) and Bax (Figure 5), but upregulated Bcl-2 (Figure 6) in both the liver and kidney tissues in comparison to the group that was given cisplatin only. The renal expression of caspase-3 (Figure 4) and Bax (Figure 5) in the *S. cornutus* (500 mg/kg) group was significantly lower than their expression in the *S. cornutus* (250 mg/kg) group. Moreover, the expression of Bcl-2 in both the liver and the kidney of the mice that received 500 mg/kg of *S. cornutus* was significantly higher than its expression in the lower dose (*S. cornutus* 250 mg/kg) group (Figure 6). Notably, the hepatic expression of caspase-3 (Figure 4) and Bcl-2 (Figure 6) in the higher dose (*S. cornutus* 500 mg/kg) group was not significantly different relative to the normal control group.

Additionally, histopathological examination of the liver tissue revealed normal architecture of the liver in the normal control group (Figure 7A), while the liver specimens of mice that were given cisplatin alone showed inflammation, foci of spotty necrosis, with congestion of central vein and dilation of sinusoidal spaces (Figure 7B). The group that received 250 mg/kg of *S. cornutus* crude extract + cisplatin showed partial improvement of the liver tissue, less infiltration of inflammatory cells, but dilated sinusoidal spaces were still detected (Figure 7C). The liver tissue of the *S. cornutus* (500 mg/kg) group showed the best improvement, with minimal infiltration of inflammatory cells and restoration of normal sinusoidal spaces (Figure 7D).

On the other hand, histopathological examination of the kidney tissue revealed normal looking glomeruli, proximal tubules, and distal tubules in the normal control group (Figure 8A). The renal injury was pronounced in the group that received cisplatin only, where patchy interstitial inflammatory cell infiltrate, congestion, focal tubular cell necrosis with condensed eosinophilic cytoplasm, and regenerative changes were detected (Figure 8B). No significant improvement was observed on examination of the kidney tissue of the mice that received the lower dose of *S. cornutus* (250 mg/kg) + cisplatin (Figure 8C), however, the higher dose (500 mg/kg) of *S. cornutus* crude extract showed improved renal tissue, with patchy interstitial inflammatory cell infiltrate, mild congestion, and minimal focal tubular cell necrosis (Figure 8D).

The hepatotoxicity and nephrotoxicity induced by cisplatin are well-documented and experimental models that have been extensively used to evaluate the protective effects of various reagents against cisplatin-induced hepato- and nephrotoxicity. Liver is the major organ in which most metabolic reactions occur. Cisplatin is metabolized in the liver by cytochrome P450 (CYP450) enzyme complex [57], where cytochrome P450 2E1 (CYP2E1) is thought to be the leading enzyme involved in cisplatin-induced hepatotoxicity [58]. Cisplatin-treated cells overexpressing CYP2E1 were proven to produce high levels of ROS [59]. In addition, cisplatin has been reported to cause direct damage to mitochondrial DNA, leading to reduction of mitochondrial protein synthesis and impairment of electron transport chain function. Such events are associated with increased intracellular ROS levels [60]. ROS play a key role in cisplatin-induced hepatotoxicity through increasing hepatic MDA [61]. The latter is the principal product of polyunsaturated fatty acid peroxidation and is considered a biomarker of lipid peroxidation and oxidative stress. MDA can react with cellular proteins and DNA, resulting in biomolecular damage [62]. It has been shown that a set of endogenous antioxidants can reduce ROS-induced cellular damage. SOD generally dismutates the superoxide anion radical into hydrogen peroxide which is degraded by catalase or glutathione peroxidase using GSH [63]. However, increased oxidative stress leads to exhaustion of GSH and inactivation of antioxidant enzymes such as SOD and catalase either by cross linking with MDA or rapid consumption of the antioxidant molecules in fighting the generated free radicals, further aggravating oxidative stress [61,64].
(Figure 4) and upregulated Bcl-2 expression (Figure 6) in the liver tissue only relative to the cisplatin control group. The higher dose (500 mg/kg) of *S. cornutus* significantly downregulated caspase-3 (Figure 4) and Bax (Figure 5), but upregulated Bcl-2 (Figure 6) in both the liver and kidney tissues in comparison to the group that was given cisplatin only. The renal expression of caspase-3 (Figure 4) and Bax (Figure 5) in the *S. cornutus* (500 mg/kg) group was significantly lower than their expression in the *S. cornutus* (250 mg/kg) group. Moreover, the expression of Bcl-2 in both the liver and the kidney of the mice that received 500 mg/kg of *S. cornutus* was significantly higher than its expression in the lower dose (*S. cornutus* 250 mg/kg) group (Figure 6). Notably, the hepatic expression of caspase-3 (Figure 4) and Bcl-2 (Figure 6) in the higher dose (*S. cornutus* 500 mg/kg) group was not significantly different relative to the normal control group.

![Figure 4. The effect of *S. cornutus* crude extract on the expression levels of caspase-3 determined by immunohistochemistry in the (A) liver and (B) kidney tissues of the experimental mice. Data of the percentage of positive stained area are expressed as mean ± SD and analyzed using one-way ANOVA followed by Bonferroni's post hoc test (n = 8). * significantly different vs. the normal control group; # significantly different vs. the cisplatin group; † significantly different vs. the *S. cornutus* (250 mg/kg) group. Differences were considered significant at p < 0.05.](image-url)
Figure 5. The effect of *S. cornutus* crude extract on the expression levels of Bax determined by immunohistochemistry in the (A) liver and (B) kidney tissues of the experimental mice. Data of the percentage of positive stained area are expressed as mean ± SD and analyzed using one-way ANOVA followed by Bonferroni’s post hoc test (*n* = 8). * significantly different vs. the normal control group; # significantly different vs. the cisplatin group; ^ significantly different vs. the *S. cornutus* (250 mg/kg) group. Differences were considered significant at *p* < 0.05.
Figure 6. The effect of *S. cornutus* crude extract on the expression levels of Bcl-2 determined by immunohistochemistry in the (A) liver and (B) kidney tissues of the experimental mice. Data of the percentage of positive stained area are expressed as mean ± SD and analyzed using one-way ANOVA followed by Bonferroni’s post hoc test (*n* = 8). * significantly different vs. the normal control group; # significantly different vs. the cisplatin group; ˆ significantly different vs. the *S. cornutus* (250 mg/kg) group. Differences were considered significant at *p* < 0.05.

Moreover, the accumulation of intracellular ROS is closely related to the induction of pro-inflammatory cytokines via NF-κB and various pro-apoptotic cellular signaling cascades [65]. NF-κB has been reported to affect downstream target genes’ expression through downregulating Nrf2 transcription and activity by competing for its transcriptional co-activator cAMP response element binding protein [66]. Interestingly, Nrf2 has been proved to maintain intracellular redox homeostasis and exert anti-inflammatory functions through regulating heme oxygenase-1 (HO-1) axis and counteracting NF-κB driven inflammatory response [67]. Cisplatin was previously reported to increase the expression of
pro-inflammatory cytokines such as TNF-α, IL-1β, and IL-6 [68,69], along with decreasing levels of the anti-inflammatory IL-10 in the liver tissue [70]. Additionally, increased levels of NO and iNOS, key mediators of both oxidative stress and inflammation, were reported in cisplatin administered rodents [71]. Moreover, cisplatin-induced oxidative stress and inflammation have been reported to produce hepatocyte apoptosis through activation of executioner caspase-3 that triggers release of cellular proteins and DNA fragmentation factors, leading to characteristic changes of apoptosis. Caspase-3 activation is mainly regulated by the Bcl-2 family proteins through activation of the pro-apoptotic protein Bax that in turn inactivates anti-apoptotic protein Bcl-2. Bax triggers a sequence of events that cause alterations in mitochondrial permeability and stimulation of cytochrome c release with subsequent activation of caspases and cell death. Such events are inhibited by Bcl-2 [72]. Cisplatin-induced hepatotoxicity was proven by increased serum levels of the hepatic enzymes ALT, AST, and ALP [73].

Figure 7. A photomicrography of liver tissue (H&E, ×200). (A) normal control group; shows normal hepatic architecture, with clear central vein (CV) and hepatocytes radially arranged in plate (black arrows), and normal sinusoidal spaces between them (red arrows). (B) cisplatin group; shows infiltration of inflammatory cells (black arrows), with congested central vein (CV) and dilated sinusoidal spaces (red arrows). (C) S. cornutus (250 mg/kg) group; shows partial improvement, less infiltration of inflammatory cells (black arrows), but still dilated sinusoidal spaces (red arrows). (D) S. cornutus (500 mg/kg) group; shows the best improvement, nearly normal hepatic architecture, and restoration of normal sinusoidal spaces (red arrows).
Antioxidants 2022, 11, x FOR PEER REVIEW 18 of 26

(A) (B)

(C) (D)

Figure 8. A photomicrography of kidney tissue (H&E, ×100). (A) normal control group; shows normal histology, with normal looking glomeruli (asterisks), proximal tubules (black arrows), and distal tubules (blue arrows). (B) cisplatin group; shows patchy interstitial inflammatory cell infiltrate (black arrows), congestion (blue arrows), focal tubular cell necrosis with condensed eosinophilic cytoplasm (green arrows), and regenerative changes with slightly basophilic cytoplasm and enlarged nuclei (double headed arrows). (C) S. cornutus (250 mg/kg) group; shows patchy interstitial inflammatory cell infiltrate (black arrows), congestion (blue arrows), focal tubular cell necrosis with condensed eosinophilic cytoplasm (green arrows), and regenerative changes with slightly basophilic cytoplasm and enlarged nuclei (double headed arrows). (D) S. cornutus (500 mg/kg) group; shows patchy interstitial inflammatory cell infiltrate (black arrows), mild congestion (blue arrows), minimal focal tubular cell necrosis (green arrows), and some regenerative changes with slightly basophilic cytoplasm and enlarged nuclei (double headed arrows).

More to the point, cisplatin is cleared by the kidneys via both glomerular filtration and tubular secretion, and it accumulates in the renal cells in concentrations higher than those in the blood [74]. Increased serum levels of creatinine and urea were detected in cisplatin-receiving rats [75]. Cisplatin is suggested to undergo metabolic activation in proximal tubular cells to highly reactive and toxic thiols, mainly through its conjugation with GSH, leading to exhaustion of the latter [76]. Production of ROS, depletion of antioxidant enzymes, and accumulation of the lipid peroxidation products are among the main mechanisms involved in cisplatin-induced nephrotoxicity [77]. Excess production of NO by iNOS enzyme was also detected following cisplatin administration [78]. Additionally, cisplatin-induced nephrotoxicity has been reported to involve nuclear and mitochondrial DNA injury, along with the induction of apoptotic and inflammatory pathways [79]. Moreover, increased NF-κB and TNF-α expression and decreased Nrf2 expression have been shown to be associated with cisplatin-induced nephrotoxicity, leading to enhanced levels of...
inflammatory cytokines [80–82]. Furthermore, increasing lines of evidence show that apoptosis is implicated in cisplatin-associated nephrotoxicity through the imbalance between the pro-apoptotic protein Bax and the anti-apoptotic protein Bcl-2, triggering cytochrome c release and caspase-3 activation [83].

A wide variety of natural reagents (i.e., plant extracts, flavonoids, phenolic compounds, terpenoids, and oils) were reported to protect against cisplatin-induced hepatotoxicity through their antioxidant, anti-inflammatory, and antiapoptotic properties [73]. Moreover, numerous natural products (flavonoids, polysaccharides, phenylpropanoids, saponins, etc.) have been shown in recent in vivo and in vitro studies to antagonize the mechanisms involved in cisplatin-induced kidney damage through their antioxidant, anti-inflammatory, and anti-apoptotic activities [84].

Antioxidant properties of Sonchus species were previously described. Examples are S. oleraceus [48], S. arvensis [49], and S. asper [50]. Interestingly, S. asper methanolic extract was reported to alleviate oxidative stress, decrease lipid peroxidation, and enhance antioxidant defenses in a model of CCl₄-induced nephrotoxicity [85]. Moreover, the methanolic extract of S. asper produced similar protective effects against CCl₄-induced oxidative damage in the liver [86]. The extract of S. oleraceus was also found to protect against kidney injury induced by ischemia-reperfusion in rats and to restore the levels of creatinine, BUN, MDA, SOD, and proinflammatory cytokines [87].

There is a deep correlation between the high content of total phenolic compounds in S. cornutus crude extract and its observed antioxidant and anti-inflammatory effects in the current work. The antioxidant capacity of polyphenols is based on their ability to inhibit enzymes involved in the production of ROS, in addition to their ROS scavenging properties, and the upregulation of the antioxidant defenses such as GSH, SOD, and catalase [88]. Polyphenols are also able to affect the production of the key inflammatory mediator NO by interfering with the activity of iNOS enzyme [89]. Considering that oxidative stress induces a variety of transcription factors, leading to increased expression of proteins involved in inflammatory pathways such as TNF-α and IL-6, the anti-inflammatory effect of polyphenols could be attributed to their radical scavenging activities and modulation of NF-κB and mitogen-activated protein kinase (MAPK) signaling pathways [90,91]. Modulation of such pathways contributes to transcriptional upregulation and increased nuclear translocation of Nrf2 consequently leading to enhanced expression of Nrf2 downstream genes, including antioxidant and phase II detoxification enzymes [92].

In agreement with the findings of the current study, some of the metabolites detected in the extract of S. cornutus by LC-MS/MS exhibited hepato- and nephroprotective effects against cisplatin-induced toxicity. For instance, rosmarinic acid was reported to protect against cisplatin-induced kidney injury in mice through amelioration of oxidative stress, reduction of the apoptotic markers p53 and phosphorylated p53, and inhibition of the expression of caspase-3, NF-kB, and TNF-α [93]. Chlorogenic acid also decreased serum creatinine and BUN levels, reduced oxidative stress and TNF-α expression, and suppressed p53, Bax, and active caspase-3 in a murine model of cisplatin-induced nephrotoxicity [94]. Additionally, it has been demonstrated that antioxidant and anti-inflammatory effects of chlorogenic acid are attributable to enhanced Nrf2 nuclear translocation and HO-1 expression and reduced IkB phosphorylation and subsequent NF-κB nuclear translocation [95]. Urosalic acid was reported to protect against cisplatin-induced nephrotoxicity through its antioxidant and anti-apoptotic activities and mitigation of the inflammatory markers IL-1β, IL-6, and TNF-α [96].

Moreover, caffeic acid has been shown to abrogate hepatorenal toxicities mediated by different toxicants by virtue of its antioxidant, anti-inflammatory, and anti-apoptotic effects [97]. It is well-established that caffeic acid effectively quenches the free radicals and acts as a chain breaking antioxidant, terminating the chain reaction of lipid peroxidation and minimizing its detrimental effects. Additionally, it was found to increase the activities of antioxidant enzymes, including SOD and catalase [98]. Additionally, antioxidant activity of caffeic acid has been reported to be attributed to its ability to phosphorylate kelch-like
ECH-associated protein-1 (Keap1), leading to its degradation, thus releasing Nrf2 from the Keap1-mediated inhibitory complex, further contributing to maintenance of the cellular antioxidant defense system [97]. In addition, caffeic acid has been demonstrated to inhibit NF-κB activation by inhibiting IkB kinase (IKK) complex activity needed to degrade IkBα, which is responsible for sequestering NF-κB in the cytoplasm, thereby mitigating pro-inflammatory cytokines expression including IL-1β and TNF-α. Importantly, caffeic acid anti-apoptotic activity has been shown to be attributed to its ability to resolve oxidative stress and inflammation, as well as repressing Bax activity, with the simultaneous increase in Bcl-2 level leading to decreased caspase-3 activity [97].

The bioactive flavonoid luteolin ameliorated oxidative/nitrosative stress, suppressed the expression of the inflammatory factors NF-κB and TNF-α, and downregulated the renal apoptotic markers p53 and caspase-3 in a mouse model of cisplatin-induced nephrotoxicity [99]. Similarly, the flavonoid fisetin restored oxidative balance, blocked the activation of NF-κB signaling, and reduced the levels of MDA, TNF-α, and iNOS in a rat model of cisplatin-induced nephrotoxicity. The antioxidant and anti-inflammatory effects of fisetin were accompanied by anti-apoptotic effects, where it decreased the renal expression of the pro-apoptotic proteins Bax, cleaved caspase-3, cleaved caspase-9 and p53, and upregulated the anti-apoptotic protein Bcl-2 [100]. The coumarin daphnetin was also shown to reduce levels of creatinine and BUN, decrease renal MDA, inhibit NF-κB, and downregulate TNF-α and IL-1β in a model of cisplatin-induced nephrotoxicity [101]. In a rat model of cisplatin-induced hepatotoxicity, fraxetin, a bioactive coumarin, enhanced the antioxidant activity and decreased the expression of caspase-3 and TNF-α in the liver [102].

4. Conclusions

In conclusion, the LC-MS/MS metabolic analysis profile revealed enrichment of *S. cornutus* (Asteraceae) with polyphenols such as anthocyanidin glycosides, coumarins, flavonoids and their respective glycosides, and phenolic acids. In vitro assays revealed that the crude extract of *S. cornutus* exhibited a significant DPPH free radical scavenging effect and a promising reducing potential, indicated by the total antioxidant capacity and ferric reducing power capacity assays. Besides, this study was the first to evaluate hepatoprotective and nephroprotective effects of *S. cornutus* extract using a mouse model of cisplatin-induced hepatotoxicity and nephrotoxicity. As per our findings, it has been clearly indicated that pretreatment with *S. cornutus* extract for 14 days before cisplatin and 7 days after cisplatin injection improved liver and kidney functions, restored oxidative stress, inflammatory, and apoptotic markers. Based on these observations, the antioxidant effects of *S. cornutus* extract against cisplatin-induced liver and kidney injuries were evidenced by its ability to scavenge free radicals, reduce oxidative stress, and elevate the activities and levels of antioxidant molecules. In addition, administration of *S. cornutus* extract effectively inhibited NF-κB signaling pathways with subsequent decrease in the pro-inflammatory cytokines’ expression including TNF-α, IL-1β and IL-6 and elevation of the anti-inflammatory cytokine IL-10. Additionally, treatment with *S. cornutus* extract led to activation of Nrf2 signaling, thereby maintaining intracellular redox homeostasis and counteracting NF-κB driven inflammatory response. Importantly, *S. cornutus* extract exerted a potential anti-apoptotic activity as indicated by repressing pro-apoptotic Bax activity with the simultaneous increase of anti-apoptotic Bcl-2 level leading to decreased caspase-3 activity. Furthermore, *S. cornutus* extract administration ameliorated the histopathological changes induced by cisplatin. Importantly, the higher dose of *S. cornutus* extract (500 mg/kg) elicited the most prominent effect, as compared to the lower dose (250 mg/kg). This study suggested that such extract might be considered as a novel therapeutic strategy against cisplatin-induced hepatoprotective and nephroprotective effects.

**Supplementary Materials:** The following supporting information can be downloaded at: [https://www.mdpi.com/article/10.3390/antiox11050819/s1](https://www.mdpi.com/article/10.3390/antiox11050819/s1), Figure S1: Chromatogram of LC-MS/MS analysis of crude extract of *Sonchus cornutus* (positive mode), Figure S2: Chromatogram of LC-MS/MS analysis of crude extract of *Sonchus cornutus* (negative mode).
MS/MS analysis of crude extract of *Sonchus cornutus* (negative mode), Table S1: GenBank accession numbers, primer sequences and annealing temperatures of the assessed genes.

**Author Contributions:** Conceptualization, S.S.E. and R.F.A.A.; methodology, M.S.G., E.T.M., S.S.E. and A.S.W.; data curation, M.S.G., A.S.W., M.A.E., A.O.N., H.A.B., R.T.M., A.E.K. and E.T.M.; writing—original draft preparation, M.S.G., E.T.M., A.S.W. and R.F.A.A.; writing—review and editing, M.S.G., A.S.W., E.T.M., R.F.A.A. and S.S.E.; resources, S.S.E., M.A.E., R.T.M., A.O.N., A.E.K. and H.A.B.; supervision, S.S.E.; project administration, S.S.E.; funding acquisition, A.E.K., A.O.N., H.A.B., R.T.M., M.A.E. and S.S.E. All authors have read and agreed to the published version of the manuscript.

**Funding:** The Deanship for Research & Innovation, Ministry of Education in Saudi Arabia funded this research work through the project number IFPRC-198-166-2020.

**Institutional Review Board Statement:** Experimental design and animal handling were carried out in accordance with Guide for the Care and Use of Laboratory Animals (8th edition, National Academies Press) and were approved by the Ethics Committee of Faculty of Pharmacy, Suez Canal University (Ethics code: 202103RA2).

**Informed Consent Statement:** Not applicable.

**Data Availability Statement:** Data is available within the article.

**Acknowledgments:** The authors extend their appreciation to the Deanship for Research & Innovation, Ministry of Education in Saudi Arabia for funding this research work through the project number IFPRC-198-166-2020 and King Abdulaziz University, DSR, Jeddah, Saudi Arabia. The authors are grateful to Malik Suliman Mohamed, Department of Pharmaceutics, Faculty of Pharmacy, Khartoum University, Sudan, for providing us the Sudanese plant *Sonchus cornutus*. Many thanks to Haider Abdelgadir and Yahia Mohammed, Medicinal and Aromatic Plants Research Institute (MAPRI), National Centre for Research, Sudan, for their taxonomical identification of *Sonchus cornutus*.

**Conflicts of Interest:** The authors declare no conflict of interest.

**References**

1. Ghosh, S. Cisplatin: The first metal based anticancer drug. *Bioorg. Chem.* 2019, 88, 102925. [CrossRef] [PubMed]

2. Singh, N.; Magotra, R.; Sharma, A.K.; Ahmed, M.; Khajuria, V. Effect of cisplatin on liver of male albino rats. *J. Evol. Med. Dent. Sci.* 2015, 4, 8993–8998. [CrossRef]

3. Abdel Moneim, A.E.; Othman, M.S.; Aref, A.M. *Azadirachta indica* attenuates cisplatin-induced nephrotoxicity and oxidative stress. *Biomed. Res. Int.* 2014, 2014, 647131. [CrossRef] [PubMed]

4. Ma, L.; Wang, H.; Wang, C.; Su, J.; Xie, Q.; Xu, L.; Yu, Y.; Liu, S.; Li, S.; Xu, Y. Failure of elevating calcium induces oxidative stress tolerance and imparts cisplatin resistance in ovarian cancer cells. *Aging Dis.* 2016, 7, 254–266. [CrossRef]

5. Abouzed, T.; Soliman, M.; Khatab, S.; Elgazzar, A.; Gouda, W.; Dorghamm, D. The protective impacts of *Ulva lactuca* against cisplatin-induced renal injury through the regulation of oxidative stress, pro-inflammatory cytokines and Bax/Bcl2 expression cascade. *Toxicol. Res.* 2022, 11, 169–178. [CrossRef]

6. Ko, J.W.; Lee, I.C.; Park, S.H.; Moon, C.; Kang, S.S.; Kim, S.H.; Kim, J.C. Protective effects of pine bark extract against cisplatin-induced hepatotoxicity and oxidative stress in rats. *Lab. Anim. Res.* 2014, 30, 174–180. [CrossRef]

7. Rolnik, A.; Olas, B. The plants of the Asteraceae family as agents in the protection of human health. *Int. J. Mol. Sci.* 2021, 22, 3009. [CrossRef]

8. Li, X.-M.; Yang, P.-L. Research progress of *Sonchus* species. *Int. J. Food Prop.* 2018, 21, 147–157. [CrossRef]

9. Farah, H.M.; Hussein, A.R.M.E.; Khalid, H.E.; Osman, H. Assessment of sub chronic toxicity of *Sonchus cornutus* in rats. *AIR* 2019, 19, 1–8. [CrossRef]

10. Abdel-Hamed, A.R.; Mehanna, E.T.; Hazem, R.M.; Badr, J.M.; Abo-Elmatty, D.M.; Abdel-Kader, M.S.; Goda, M.S. *Plicosepalus acacia* extract and its major constituents, methyl gallate and quercetin, potentiate therapeutic angiogenesis in diabetic hind limb ischemia: HPTLC quantification and LC-MS/MS metabolic profiling. *Antioxidants* 2021, 10, 1701. [CrossRef]

11. Goda, M.S.; Nafie, M.S.; Awad, B.M.; Abdel-Kader, M.S.; Ibrahim, A.K.; Badr, J.M.; Eltamany, E.E. In vitro and in vivo studies of anti-lung cancer activity of *Artemesia judaica* L. crude extract combined with LC-MS/MS metabolic profiling, docking simulation and HPLC-DAD quantification. *Antioxidants* 2022, 11, 17. [CrossRef] [PubMed]

12. Abdelhameed, R.F.A.; Habib, E.S.; Goda, M.S.; Fahim, J.R.; Hassanean, H.A.; Eltamany, E.E.; Ibrahim, A.K.; AboulMagd, A.M.; Fayez, S.; El-kader, A.M.A.; et al. Thalassostero1, a new cytotoxic aromatase inhibitor ergosterol derivative from the Red Sea seagrass *Thalassodendron ciliatum*. *Mar. Drugs* 2020, 18, 354. [CrossRef] [PubMed]

13. Eltamany, E.E.; Elhady, S.S.; Goda, M.S.; Aly, O.M.; Habib, E.S.; Ibrahim, A.K.; Hassanean, H.A.; Abdelmohsen, U.R.; Safo, M.K.; Ahmed, S.A. Chemical composition of the Red Sea green algae *Ulva lactuca*: Isolation and in silico studies of new anti-COVID-19 ceramides. *Metabolites* 2021, 11, 816. [CrossRef] [PubMed]
14. Elhady, S.S.; Habib, E.S.; Abdelhameed, R.F.A.; Goda, M.S.; Hazem, R.M.; Mehanna, E.T.; Helal, M.A.; Hosny, K.M.; Diri, R.M.; Hassanean, H.A.; et al. Anticancer effects of new ceramides isolated from the Red Sea red alga *Hypnea musciformis* in a model of Ehrlich ascites carcinoma: LC-HRMS analysis profile and molecular modeling. *Mar. Drugs* **2022**, *20*, 63. [CrossRef] [PubMed]

15. Hatami, T.; Emami, S.A.; Miraghaei, S.S.; Mojarad, M. Total Phenolic contents and antioxidant activities of different extracts and fractions from the aerial parts of *Artemisia biennis* Willd. *Iran. J. Pharm. Res.* **2014**, *13*, 551–559. [PubMed]

16. Kamtekar, S.; Keer, V.; Patil, V. Estimation of phenolic content, flavonoid content, antioxidant and alpha amylase inhibitory activity of marketed polyherbal formulation. *J. Appl. Pharm. Sci.* **2014**, *4*, 61–65. [CrossRef]

17. Kasangana, P.B.; Haddad, P.S.; Stevanovic, T. Study of polyphenol content and antioxidant capacity of *Myrianthus arbores* (Cereciaceae) root bark extracts. *Antioxidants* **2015**, *4*, 410–426. [CrossRef]

18. Batool, R.; Khan, M.R.; Sajid, M.; Ali, S.; Zahra, Z. Estimation of phytochemical constituents and in vitro antioxidant potencies of *Brachyhotyon populneus* (Schott & Endl.) R.Br. *BMC Chem.* **2019**, *13*, 32. [CrossRef]

19. Eltamany, E.E.; Elhady, S.S.; Ahmed, H.A.; Badr, J.M.; Noor, A.O.; Ahmed, S.A.; Nafie, M.S. Chemical profiling, antioxidant, anti-inflammatory, and protective properties of daphnetin (Cunoniaceae). *Antioxidants* **2020**, *9*, 1286. [CrossRef]

20. Leta, B.; Kenenisa, C.; Wondimnew, T.; Sime, T. Evaluation of renoprotective effects of our locally grown green coffee beans against cisplatin-induced nephrotoxicity in Swiss albino mice. *J. Nephrol.* **2021**, *2021*, 2805068. [CrossRef]

21. Schmittgen, T.D.; Livak, K.J. Analyzing real-time PCR data by the comparative CT method. *Nat. Protoc.* **2008**, *3*, 1101–1108. [CrossRef] [PubMed]

22. Ling, Y.; Ren, C.; Mallory, S.R.; Ugalde, C.M.; Pei, P.; Saradhi, U.V.R.V.; Stoner, G.D.; Chan, K.K.; Liu, Z. A rapid and sensitive LC–MS/MS method for quantification of four anthocyanins and its application in a clinical pharmacology study of a bio adhesive black raspberry gel. *J. Chromatogr. B* **2009**, *877*, 4027–4034. [CrossRef] [PubMed]

23. Giordano, L.; Coletta, W.; Rapisarda, P.; Donati, M.B.; Rotilio, D. Development and validation of an LC-MS/MS method for the simultaneous determination of delphinidin-3-glucoside, cyanidin-3-glucoside, and cyanidin-3-(6-malonylglucoside) in human plasma and urine after blood orange juice administration. *J. Sep. Sci.* **2007**, *30*, 3127–3136. [CrossRef] [PubMed]

24. Scorrano, S.; Lazzoi, M.R.; Mergola, L.; Bello, M.P.D.; Sole, R.D.; Vasapollo, G. Anthocyanins profile by Q-TOF LC/MS in *Myrtus communis* berries from Salento area. *Food Anal. Methods* **2017**, *10*, 2404–2411. [CrossRef]

25. Wang, Z.; Wang, C.; He, B.; Zhang, W.; Liu, L.; Deng, M.; Lù, M.; Qi, X.; Liang, S. Determination of daphnetin and its 8-O-methylated metabolite in rat plasma by UFLC/MS/MS: Application to a pharmacokinetic study. *Chromatographia* **2022**, *85*, 333–341. [CrossRef]

26. Wang, Z.; Zhu, W.; Liu, H.; Wu, G.; Song, M.; Yang, B.; Yang, D.; Wang, Q.; Kuang, H. Simultaneous determination of aesculin, aesculetin, fraxetin, fraxin and polydatin in beagle dog plasma by UPLC-ESI-MS/MS and its application in a pharmacokinetic study after oral administration extracts of *Ledum palustre* L. *Molecules* **2018**, *23*, 2285. [CrossRef]

27. Abu-Reidah, I.M.; Ali-Shtayeh, M.S.; Jamous, R.M.; Arr, A.; Alsharif, A. Determination of bioactive components from *Rhus coriaria* food matrix by liquid chromatography/tandem mass spectrometry. *J. Pharm. Biomed. Anal.* **2010**, *52*, 625–630. [CrossRef]

28. Li, X.; Yu, C.; Sun, W.; Liu, G.; Jia, J.; Wang, Y. Simultaneous determination of magnesium lithospermate B, rosmarinic acid, and lithospermic acid in beagle dog serum by LC/MS/MS: Application to pharmacokinetic study of Shuang-huang-lian black raspberry gel. *J. Chromatogr. B* **2011**, *877*, 558–563. [CrossRef]

29. Ye, J.X.; Wei, W.; Quan, L.H.; Liu, C.Y.; Chang, Q.; Liao, Y.H. An LC–MS/MS method for the simultaneous determination of chlorogenic acid, forsythiaside A and baicalin in rat plasma and its application to pharmacokinetic study of Shuang-huang-lian in rats. *J. Pharm. Biomed. Anal.* **2010**, *52*, 625–630. [CrossRef]

30. Adisaswattana, S.; Yibchok-Anun, S.; Charoenlerklertk, P.; Wongsa-isirapat, N. Cyanidin-3-rutinoside alleviates postprandial hyperglycemia and its synergism by acarbose with inhibition of intestinal α-glucosidase. *J. Clin. Biochem. Nutr.* **2011**, *49*, 36–41. [CrossRef]

31. Yang, X.; Luo, E.; Liu, X.; Han, B.; Yu, X.; Peng, X. Delphinidin-3-glucoside suppresses breast carcinogenesis by activating the Akt/HOTAIR signaling pathway. *BMC Cancer* **2016**, *16*, 423. [CrossRef] [PubMed]

32. Sari, D.R.T.; Cairns, J.R.K.; Safitri, A.; Patchiyah, F. Virtual prediction of the delphinidin-3-O-glucoside and peonidin-3-O-glucoside as anti-inflammatory of TNF-α signaling. *Acta Inform. Med.* **2019**, *27*, 152–157. [CrossRef] [PubMed]

33. Tan, J.; Li, Y.; Hou, D.X.; Wu, S. The effects and mechanisms of cyanidin-3-glucoside and its phenolic metabolites in maintaining intestinal integrity. *Antioxidants* **2019**, *8*, 479. [CrossRef] [PubMed]

34. Abdelmohsen, U.R.; Alboby, A.; Abdulrazik, B.S.; Bayoumi, S.A.L.; Malak, L.G.; Khalaf, I.S.A.; Bringmann, G.; Farag, S.F. Natural coumarins as potential anti-SARS-CoV-2 agents supported by docking analysis. *RSC Adv.* **2021**, *11*, 16970–16979. [CrossRef]

35. Solís-Salas, L.M.; Sierra-Rivera, C.A.; Cobos-Puc, L.E.; Asccasio-Valdés, J.A.; Silva-Belmares, S.Y. Antibacterial potential of *Myrianthus arbores* root bark extracts. *Antibiotics* **2021**, *10*, 508. [CrossRef] [PubMed]

36. Yu, W.; Lu, Z.; Zhang, H.; Kang, Y.; Mao, Y.; Wang, H.; Ge, W.; Shi, L. Anti-inflammatory, and protective properties of daphnetin in endotoxin-induced lung injury. *J. Agric. Food Chem.* **2014**, *62*, 12315–12325. [CrossRef] [PubMed]

37. Wang, G.; Fang, J.; Hu, X.; Nie, T.; Lu, X.; Li, X.; Wang, X.; Lu, Y.; Yang, X.; Jiang, J.; et al. Daphnetin: A novel anti-*Helicobacter pylori* agent. *Int. J. Mol. Sci.* **2020**, *20*, 850. [CrossRef]
38. Song, B.; Wang, Z.; Liu, Y.; Xu, S.; Huang, G.; Xiong, Y.; Zhang, S.; Xu, L.; Deng, Z.; Guan, S. Immunosuppressive activity of daphnetin, one of coumarin derivatives, is mediated through suppression of NF-κB and NFAT signaling pathways in mouse T cells. *PLoS ONE* **2014, 9**, e96302. [CrossRef]

39. Wang, H.; Zou, D.; Xie, K.; Xie, M. Antibacterial mechanism of fraxetin against *Staphylococcus aureus*. *Mol. Med. Rep.* **2014, 10**, 2341–2345. [CrossRef]

40. Lee, M.; Yang, C.; Park, S.; Song, G.; Lim, W. Fraxetin induces cell death in colon cancer cells via mitochondria dysfunction and enhances therapeutic effects in 5-fluorouracil resistant cells. *J. Cell. Biochem.* **2022, 123**, 469–480. [CrossRef]

41. Lam, K.Y.; Ling, A.P.K.; Koh, R.Y.; Wong, Y.P.; Say, Y.H. A Review on medicinal properties of orientin. *Adv. Pharmacol. Sci.* **2016, 2016**, 4104595. [CrossRef] [PubMed]

42. Ziyani, L.; Yongmei, Z.; Nan, Z.; Ning, T.; Baolin, L. Evaluation of the anti-inflammatory activity of luteolin in experimental animal models. *Planta Med.* **2007, 73**, 221–226. [CrossRef] [PubMed]

43. Park, H.-H.; Lee, S.; Oh, J.-M.; Lee, M.-S.; Yoon, K.-H.; Park, B.H.; Kim, J.W.; Song, H.; Kim, S.-H. Anti-inflammatory activity of fisetin in human mast cells (HMC-1). *Pharmacol. Res.* **2007, 55**, 31–37. [CrossRef] [PubMed]

44. Espindola, K.M.M.; Ferreira, R.G.; Narvaez, L.E.M.; Silva Rosario, A.C.R.; da Silva, A.H.M.; Silva, A.G.B.; Vieira, A.P.O.; Monteiro, M.C. Chemical and pharmacological aspects of caffeic acid and its activity in hepatocarcinoma. *Front. Oncol.* **2019, 9**, 541. [CrossRef]

45. Iswandumana, R.; Pham, B.T.; van Haaften, W.T.; Luangmonkong, T.; Oosterhuis, D.; Mutsaers, H.A.M.; Olinga, P. Organ- and species-specific biological activity of rosmarinic acid. *Toxicol. In Vitro* **2016, 32**, 261–268. [CrossRef]

46. Naveed, M.; Hejazi, V.; Abbas, M.; Kamboh, A.A.; Khan, G.J.; Shumzaid, M.; Ahmad, F.; Babazadeh, D.; FangFang, Z.; Modarresi-Ghazani, F.; et al. Chlorogenic acid (CGA): A pharmacological review and call for further research. *Biomed. Pharmacother.* **2018, 97**, 67–74. [CrossRef]

47. Lee, S.Y.; Kim, Y.J.; Chung, S.O.; Park, S.U. Recent studies on ursolic acid and its biological and pharmacological activity. *EXCLI J.* **2016, 15**, 221–228. [CrossRef]

48. Yin, J.; Kwon, G.J.; Wang, M.H. The antioxidant and cytotoxic activities of *Sonchus oleraceus* L. extracts. *Nutr. Res. Pract.* **2007, 1**, 189–194. [CrossRef]

49. Khan, R.A. Evaluation of flavonoids and diverse antioxidant activities of *Sonchus arvensis*. *Chem. Cent. J.* **2012, 6**, 126. [CrossRef]

50. Khan, R.A. Protective effects of *Sonchus asper* (L.) Hill, (Asteraceae) against CCl₄-induced oxidative stress in the thyroid tissue of rats. *BM Complement. Altern Med.* **2012, 12**, 181. [CrossRef]

51. Minatel, I.O.; Borges, C.V.; Ferreira, M.I.; Gomez, H.A.; Chen, C.-Y.O.; Lima, G.P. Phenolic compounds: Functional properties, impact of processing and bioavailability. In *Phenolic Compounds—Biological Activity*, 1st ed.; Soto-Hernandez, M., Palma-Tenango, M., del Rosario Gracia Mateos, M., Eds.; InTech: Nappanee, IN, USA, 2017; pp. 1–24. [CrossRef]

52. Forman, H.J.; Zhang, H. Targeting oxidative stress in disease: Promise and limitations of antioxidant therapy. *Nat. Rev. Drug Discov.* **2021, 20**, 689–709. [CrossRef] [PubMed]

53. Khan, R.A.; Khan, M.R.; Sahreen, S.; Ahmed, M. Evaluation of phenolic contents and antioxidant activity of various solvent extracts of *Sonchus asper* (L.) Hill. *Chem. Cent. J.* **2012, 6**, 12. [CrossRef] [PubMed]

54. Gomaa, N.H.; Hassan, M.O.; Fahyny, G.M.; Gonzalez, L.; hammouda, O.; Atteya, A.M. Allelopathic effects of *Sonchus oleraceus* L. on the germination and seedling growth of weed species. *Acta Bot. Bras.* **2014, 28**, 408–416. [CrossRef]

55. Fouad, H.; Habib, E.S.; Ahmed, S.A. Phytochemistry and pharmacological effects of plants in genus *Sonchus* (Asteraceae). *Rec. Pharm. Biomed. Sci.* **2020, 4**, 40–50.

56. Rahman, M.M.; Islam, M.B.; Biswas, M.; Alam, A.H.M.K. In vitro antioxidant and free radical scavenging activity of different parts of *Tabebuia pallida* growing in Bangladesh. *BM Res. Notes* **2015, 8**, 621. [CrossRef]

57. Quintanilha, J.C.F.; de Sousa, V.M.; Visacri, M.B.; Amaral, R.M.M.; Zambrano, T.; Salazar, L.A.; Moriel, P. Involvement of cytochrome P450 in cisplatin treatment: Implications for toxicity. *Cancer Chemother. Pharmacol.* **2017, 80**, 223–233. [CrossRef]

58. Lu, Y.; Cederbaum, A.I. Cytochrome P450s and alcoholic liver disease. *Curr. Pharm. Des.* **2018, 24**, 1502–1517. [CrossRef]

59. Lu, Y.; Cederbaum, A.I. Cisplatin-induced hepatotoxicity is enhanced by elevated expression of cytochrome P450 2E1. *Toxicol. Sci.* **2006, 89**, 515–523. [CrossRef]

60. Marullo, R.; Werner, E.; Degtyareva, N.; Moore, B.; Altavilla, G.; Ramalingam, S.S.; Doetsch, P.W. Cisplatin induces a mitochondrial-ROS response that contributes to cytotoxicity depending on mitochondrial redox status and bioenergetic functions. *PLoS ONE* **2013, 8**, e81162. [CrossRef]

61. Ahmadiipour, A.; Sharififar, F.; Nakhaipour, F.; Samianian, M.; Karami-Mohajeri, S. Hepatoprotective effect of Zataria Multiflora Boissisn cisplatin-induced oxidative stress in male rat. *J. Med. Life* **2015, 8**, 275–281.

62. Ayala, A.; Muñoz, M.F.; Argüelles, S. Lipid peroxidation: Production, metabolism, and signaling mechanisms of malondialdehyde and 4-hydroxy-2-nonenal. *Oxid. Med. Cell Longev.* **2014, 2014**, 360438. [CrossRef] [PubMed]

63. Kurutas, E.B. The importance of antioxidants which play the role in cellular response against oxidative/nitrosative stress: Current state. *Nutr. J.* **2015, 15**, 71. [CrossRef] [PubMed]

64. Noeman, S.A.; Hamooda, H.E.; Baalash, A.A. Biochemical study of oxidative stress markers in the liver, kidney and heart of high fat diet induced obesity in rats. *Diabetol. Metab. Syndr.* **2011, 3**, 17. [CrossRef] [PubMed]
65. Sadhukhan, P.; Saha, S.; Dutta, S.; Sil, P.C. Mangiferin ameliorates cisplatin induced acute kidney injury by upregulating Nrf-2 via the activation of PI3K and exhibits synergistic anticancer activity with cisplatin. *Front. Pharmacol.* 2018, 9, 638. [CrossRef] [PubMed]

66. Yan, M.; Gao, W.; Guo, L.; Yang, Y.; Wang, Y.; Gong, H.; Xia, S.; Zhang, B.-K. Dissecting the crosstalk between Nrf2 and NF-κB response pathways in drug-induced toxicity. *Front. Cell Dev. Biol.* 2021, 9, 809952. [CrossRef]

67. Saha, S.; Buttari, B.; Panieri, E.; Profumo, E.; Saso, L. An overview of Nrf2 signaling pathway and its role in inflammation. *Molecules* 2020, 25, 5474. [CrossRef]

68. Cüre, M.C.; Cüre, E.; Kalkan, Y.; Kırbas, A.; Tümkaya, L.; Yılmaz, A.; Türkylmaz, A.K.; Şehitoğlu, İ.; Yüce, S. Infliximab modulates cisplatin-induced hepatotoxicity in rats. *Balk. Med. J.* 2016, 33, 504–511. [CrossRef]

69. Bilgic, Y.; Akbulut, S.; Aksungur, Z.; Erdemli, M.E.; Ozhan, O.; Parlakpinar, H.; Vardi, N.; Turkoz, Y. Protective effect of dexpanthenol against cisplatin-induced hepatotoxicity. *Exp. Ther. Med.* 2018, 16, 4049–4057. [CrossRef]

70. Omar, H.A.; Mohamed, W.R.; Arab, H.H.; Arafa, E.-S.A. Tangeretin alleviates cisplatin-induced acute hepatic injury in rats: Targeting MAPKs and apoptosis. *PLoS ONE* 2016, 11, e0151649. [CrossRef]

71. El-Shitany, N.A.; Eid, B. Proanthocyanidin protects against cisplatin-induced oxidative liver damage through inhibition of inflammation and NF-κB/TLR-4 pathway. *Environ. Toxicol.* 2017, 32, 1952–1963. [CrossRef]

72. Aboraya, D.M.; El Baz, A.; Risha, E.F.; Abdelhamid, F.M. Hesperidin ameliorates cisplatin induced hepatotoxicity and attenuates oxidative damage, cell apoptosis, and inflammation in rats. *Saud. J. Biol. Sci.* 2022, 29, 3157–3166. [CrossRef]

73. Abd Rashid, N.; Abd Halim, S.A.S.; Teoh, S.L.; Budin, S.B.; Hussan, F.; Adib Ridzuan, N.R.; Abdul Jalil, N.A. The role of natural antioxidants in cisplatin-induced hepatotoxicity. *Biomed. Pharmacother.* 2021, 144, 112328. [CrossRef] [PubMed]

74. Yao, X.; Panichipsal, K.; Kurtzman, N.; Nugent, K. Cisplatin nephrotoxicity: A review. *Am. J. Med. Sci.* 2007, 334, 115–124. [CrossRef] [PubMed]

75. Santos, N.A.; Catão, C.S.; Martins, N.M.; Curti, C.; Bianchi, M.L.; Santos, A.C. Cisplatin-induced nephrotoxicity is associated with oxidative stress, redox state unbalance, impairment of energetic metabolism and apoptosis in rat kidney mitochondria. *Arch. Toxicol.* 2007, 81, 95–104. [CrossRef]

76. Townsend, D.M.; Deng, M.; Zhang, L.; Lapus, M.G.; Hanigan, M.H. Metabolism of cisplatin to a nephrotoxin in proximal tubule cells. *J. Am. Soc. Nephrol.* 2003, 14, 1–10. [CrossRef] [PubMed]

77. Peres, L.A.; da Cunha, A.D.; Jr. Acute nephrotoxicity of cisplatin: Molecular mechanisms. *J. Bras. Nefrol.* 2013, 35, 332–340. [CrossRef]

78. Morsy, M.A.; Heeba, G.H. Nebivolol ameliorates cisplatin-induced nephrotoxicity in rats. *Basic Clin. Pharmacol. Toxicol.* 2016, 118, 449–455. [CrossRef]

79. Miller, R.P.; Tadagavadi, R.K.; Ramesh, G.; Reeves, W.B. Mechanisms of cisplatin nephrotoxicity. *Toxins* 2010, 2, 2490–2518. [CrossRef]

80. Zhang, B.; Ramesh, G.; Norbury, C.C.; Reeves, W.B. Cisplatin-induced nephrotoxicity is mediated by tumor necrosis factor-alpha produced by renal parenchymal cells. *Kidney Int.* 2007, 72, 37–44. [CrossRef]

81. Hao, Y.; Miao, J.; Liu, W.; Peng, L.; Chen, Y.; Zhong, Q. Formononetin protects against cisplatin-induced acute kidney injury through activation of the PPARα/Nrf2/HO-1/NQO1 pathway. *Int. J. Mol. Med.* 2018, 449, 1–10. [CrossRef] [PubMed]

82. McSweeney, K.R.; Gadanec, L.K.; Qaradakhi, T.; Ali, B.A.; Zulli, A.; Apostolopoulos, V. Mechanisms of cisplatin-induced acute kidney injury: Pathological mechanisms, pharmacological interventions, and genetic mitigations. *Cancers* 2013, 15, 1572. [CrossRef] [PubMed]

83. Wang, H.; Xia, W.; Long, G.; Pei, Z.; Li, Y.; Wu, M.; Wang, Q.; Zhang, Y.; Jia, Z.; Chen, H. Isoquercitrin ameliorates cisplatin-induced nephrotoxicity via the inhibition of apoptosis, inflammation, and oxidative stress. *Front. Pharmacol.* 2020, 11, 599416. [CrossRef] [PubMed]

84. Fang, C.Y.; Lou, D.Y.; Zhou, L.Q.; Wang, J.C.; Yang, B.; He, Q.J.; Wang, J.J.; Weng, Q.J. Natural products: Potential treatments for cisplatin-induced nephrotoxicity. *Acta Pharmacol. Sin.* 2021, 42, 1951–1969. [CrossRef] [PubMed]

85. Khan, R.A.; Khan, M.R.; Sahreen, S.; Bokhari, J. Prevention of CCl4-induced nephrotoxicity with *Sonchus asper* in rat. *Food Chem. Toxicol.* 2010, 48, 2469–2476. [CrossRef]

86. Khan, R.A.; Khan, M.R.; Sahreen, S.; Shah, N.A. Hepatoprotective activity of *Sonchus asper* against carbon tetrachloride-induced injuries in male rats: A randomized controlled trial. *BM Complement. Altern. Med.* 2012, 12, 90. [CrossRef] [PubMed]

87. Torres-González, L.; Cienfuegos-Pecina, E.; Perales-Quintana, M.M.; Alamán-Galván, G.; Muñoz-Espinosa, L.E.; Pérez-Rodríguez, E.; Cordero-Pérez, P. Nephroprotective effect of *Sonchus oleraceus* extract against kidney injury induced by ischemia-reperfusion in wistar rats. *Oxid. Med. Cell. Longev.* 2018, 2018, 9572803. [CrossRef] [PubMed]

88. Mishra, A.; Sharma, A.K.; Kumar, S.; Saxena, A.K.; Pandey, A.K. Bauhinia variegata leaf extracts exhibit considerable antibacterial, antioxidant, and anticancer activities. *Biomed. Res. Int.* 2013, 2013, 915436. [CrossRef]

89. Nijveelt, R.J.; van Nood, E.; van Hoorn, D.; Boelens, P.G.; van Norren, K.; van Leeuwen, P.A. Flavonoids: A review of probable mechanisms of action and potential applications. *Am. J. Clin. Nutr.* 2001, 74, 418–425. [CrossRef]

90. Santangelo, C.; Vári, R.; Scaccizcchio, B.; Di Benedetto, R.; Filesi, C.; Masella, R. Polyphenols, intracellular signaling and inflammation. *Ann. Ist. Super. Sanita* 2007, 43, 394–405. [CrossRef]

91. Hussain, T.; Tan, B.; Yin, Y.; Blachier, F.; Tossou, M.C.; Rahu, N. Oxidative stress, and inflammation: What polyphenols can do for us? *Oxid. Med. Cell. Longev.* 2016, 2016, 7432797. [CrossRef]
92. Soares, E.R.; Monteiro, E.B.; Grazielle, F.; Inada, K.O.; Torres, A.G.; Perrone, D.; Soulage, C.O.; Monteiro, M.C.; Resende, A.C.; Moura-Nunes, N.; et al. Up-regulation of Nrf2-antioxidant signaling by Açaí (Euterpe oleracea Mart.) extract prevents oxidative stress in human endothelial cells. J. Funct. Foods 2017, 37, 107–115. [CrossRef]

93. Domitrović, R.; Potočnjak, I.; Crnčević-Orlić, Z.; Škoda, M. Nephroprotective activities of rosmarinic acid against cisplatin-induced kidney injury in mice. Food Chem. Toxicol. 2014, 66, 321–328. [CrossRef] [PubMed]

94. Domitrović, R.; Cvijanović, O.; Šušnić, V.; Katalinić, N. Renoprotective mechanisms of chlorogenic acid in cisplatin-induced kidney injury. Toxicology 2014, 324, 98–107. [CrossRef] [PubMed]

95. Bao, L.; Li, J.; Zha, D.; Zhang, L.; Gao, P.; Yao, T.; Wu, X. Chlorogenic acid prevents diabetic nephropathy by inhibiting oxidative stress and inflammation through modulation of the Nrf2/HO-1 and NF-kB pathways. Int. Immunopharmacol. 2018, 54, 245–253. [CrossRef] [PubMed]

96. Tripathi, P.; Alshahrani, S. Mitigation of ILβ-1, ILβ-6, TNF-α, and markers of apoptosis by ursolic acid against cisplatin-induced oxidative stress and nephrotoxicity in rats. Hum. Exp. Toxicol. 2021, 40, S397–S405. [CrossRef]

97. Owumi, S.E.; Irozuru, C.E.; Arunsi, U.O.; Oyelere, A.K. Caffeic acid protects against DNA damage, oxidative and inflammatory mediated toxicities, and upregulated caspases activation in the hepatorenal system of rats treated with aflatoxin B1. Toxicon 2022, 207, 1–12. [CrossRef]

98. Pari, L.; Prasath, A. Efficacy of caffeic acid in preventing nickel induced oxidative damage in liver of rats. Chem. Biol. Interact 2008, 173, 77–83. [CrossRef]

99. Domitrović, R.; Cvijanović, O.; Pugel, E.P.; Zagorac, G.B.; Mahmutefendić, H.; Škoda, M. Luteolin ameliorates cisplatin-induced nephrotoxicity in mice through inhibition of platinum accumulation, inflammation, and apoptosis in the kidney. Toxicology 2013, 310, 115–123. [CrossRef]

100. Sahu, B.D.; Kalvala, A.K.; Koneru, M.; Mahesh Kumar, J.; Kuncha, M.; Rachamalla, S.S.; Sistla, R. Ameliorative effect of fisetin on cisplatin-induced nephrotoxicity in rats via modulation of NF-κB activation and antioxidant defence. PLoS ONE 2014, 9, e105070. [CrossRef]

101. Zhang, L.; Gu, Y.; Li, H.; Cao, H.; Liu, B.; Zhang, H.; Shao, F. Daphnetin protects against cisplatin-induced nephrotoxicity by inhibiting inflammatory and oxidative response. Int. Immunopharmacol. 2018, 65, 402–407. [CrossRef]

102. Ekinci-Akdemi, R.F.N.; Bi Ngöl, Ç.; Yıldırım, S.; Kandemi, R.F.M.; Küçükler, S.; Sağlam, Y.S. The investigation of the effect of fraxin on hepatotoxicity induced by cisplatin in rats. Iran. J. Basic Med. Sci. 2020, 23, 1382–1387. [CrossRef]